FDA Reaffirms It Will Not Regulate Hemp Cannabinoids as Supplements or Food

The U.S. Food and Drug Administration has continued to maintain that hemp-derived cannabinoids — including CBD, THCA, and other minor cannabinoids — cannot be lawfully marketed as dietary supplements or added to conventional food without new regulatory authority from Congress.

Silver Spring, Md. — November 19, 2024. FDA reaffirmed its long-standing position that the agency does not have a regulatory pathway for hemp-derived cannabinoids — including CBD, THCA, CBG, CBN, and others — in food or dietary supplements under the Federal Food, Drug, and Cosmetic Act.

The agency first articulated this position formally in January 2023, when then-Principal Deputy Commissioner Janet Woodcock announced FDA had concluded that the existing dietary-supplement and food-additive frameworks were “not appropriate” for CBD and that a new pathway from Congress was required. FDA has since extended that framing to other hemp-derived cannabinoids, including the intoxicating compounds that have grown in commercial prominence since the 2018 Farm Bill.

In practical terms, FDA’s stance means three things. First, the agency continues to issue warning letters to companies that make explicit disease-treatment claims about hemp cannabinoids — that authority is unambiguous. Second, FDA has declined to enforce a blanket prohibition on hemp cannabinoids in food and supplements, citing limited resources and stating that enforcement will focus on products posing the greatest risk to public health (products marketed to children, products with overt drug claims, products with contamination). Third, FDA defers questions about state-level retail regulation of consumable hemp products to state agencies.

The result is a regulatory gray zone that has persisted for the entire post-2018 hemp market. Brands ship hemp-derived cannabinoid products in food and supplement-like formats; FDA issues occasional warning letters; states pass their own labeling, dosing, and age-gating rules to fill the gap.

According to Marijuana Moment and Cannabis Wire, industry trade groups continue to lobby for a congressional fix — most often via the Farm Bill or stand-alone legislation — that would create a clear FDA pathway. As of late 2024, no such pathway had been enacted.

What it means for consumers

If you buy a THCA gummy or hemp-derived CBD tincture, you are buying a product that is not FDA-approved as a supplement or food additive. That doesn’t mean the product is unsafe — many reputable brands publish Certificates of Analysis showing potency and contaminant testing. But there is no federal premarket review.

Treat product labels with appropriate skepticism. Brands cannot legally claim that hemp cannabinoids treat, cure, or prevent any disease. If a product label does, that’s both an FDA red flag and a sign the brand is operating outside compliance norms.

Sources

• FDA — Cannabis and Cannabis-Derived Products
• Marijuana Moment — FDA coverage
• Cannabis Wire

Related

• How to Read a THCA Certificate of Analysis
• What Is the THCA Loophole?
• Are THCA Edibles Legal?